中国P站

liquid biopsy; orthopedic oncology; circulating tumor DNA; sarcoma; bone cancer; non-invasive diagnostics; ctDNA; CTCs; tumor monitoring; personalized oncology

Introduction

Orthopedic oncology has traditionally relied on imaging modalities and surgical biopsy to diagnose and monitor bone and soft tissue tumors. While effective, these methods often involve significant patient discomfort, risk of complications, and limited ability to capture tumor heterogeneity [1]. Recent advancements in molecular oncology have led to the development of liquid biopsy a minimally invasive technique that analyzes tumor-derived material from blood and other body fluids. This breakthrough holds transformative potential for the field of orthopedic oncology, especially in tracking complex and aggressive tumors such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. Liquid biopsy provides a dynamic view of the tumor genome, allowing clinicians to detect mutations, monitor treatment response, and identify emerging resistance—all without repeated surgical interventions [2].

Description

Liquid biopsy involves the detection and analysis of biomarkers released by tumors into the bloodstream or other bodily fluids. Key components include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA, proteins, and exosomes. These elements can provide valuable information about the genetic and epigenetic landscape of tumors. In orthopedic oncology, the clinical utility of liquid biopsy is being investigated for diagnosis, prognosis, treatment monitoring, and surveillance [3].

ctDNA, which is fragmented DNA shed by tumor cells, has gained particular attention for its ability to reflect the mutational profile of the tumor in real time. The analysis of ctDNA can reveal genetic alterations such as TP53, RB1, or IDH mutations, which are often associated with bone malignancies [4]. Moreover, ctDNA levels correlate with tumor burden and can be used to assess treatment efficacy or detect minimal residual disease.

Circulating tumor cells, though rarer and more challenging to isolate, offer complementary insights . These cells can be cultured and analyzed to study tumor behavior, metastatic potential, and drug resistance mechanisms. The integration of exosomal RNA and protein biomarkers further enriches the molecular information available through liquid biopsy, providing a holistic view of tumor biology [5].

In the context of orthopedic oncology, liquid biopsy is particularly valuable for tumors located in anatomically difficult areas or in patients for whom surgical biopsy is high-risk. Pediatric patients, for example, benefit from reduced exposure to invasive procedures and anesthesia. Additionally, liquid biopsy allows for serial sampling, which facilitates longitudinal monitoring without repeated biopsies [6].

Discussion

The potential of liquid biopsy in orthopedic oncology is multifaceted. First, it enhances diagnostic accuracy by capturing genetic mutations and tumor-specific markers that may be missed in single-site tissue biopsies due to tumor heterogeneity. Second, it allows for real-time assessment of treatment response, enabling clinicians to tailor therapies based on evolving tumor profiles. This is particularly relevant in sarcomas, which often require multimodal treatments including surgery, chemotherapy, and radiation [7].

In the management of metastatic bone disease, liquid biopsy can detect early signs of systemic spread, even before lesions become radiographically apparent. This early detection is crucial in adjusting therapeutic strategies and improving patient outcomes. Moreover, in patients with recurrent tumors or poor surgical candidacy, liquid biopsy provides a less invasive option to guide re-treatment decisions. Clinical trials are increasingly incorporating liquid biopsy to stratify patients, monitor therapeutic efficacy, and assess resistance mechanisms [8]. For instance, trials evaluating targeted therapies for bone sarcomas often utilize ctDNA to identify actionable mutations or to track changes in tumor burden over time. Despite its promise, liquid biopsy is not without challenges. Technical limitations include low abundance of ctDNA in early-stage tumors, potential contamination with non-tumor DNA, and variability in assay sensitivity and specificity. Standardization of collection, processing, and analysis protocols remains an ongoing issue, particularly in the context of rare tumors like sarcomas. Furthermore, the interpretation of liquid biopsy results requires careful correlation with clinical and radiological findings to avoid overdiagnosis or inappropriate treatment changes [9].

Cost and accessibility are also considerations, as advanced sequencing technologies may not be readily available in all healthcare settings. Nevertheless, as technology advances and costs decrease, the integration of liquid biopsy into routine orthopedic oncology practice becomes increasingly feasible. Research into combining liquid biopsy with other biomarkers and imaging techniques is ongoing. For example, integrating ctDNA analysis with PET-CT imaging may provide synergistic insights into tumor metabolism and molecular characteristics. Additionally, artificial intelligence and machine learning are being employed to enhance the predictive power of liquid biopsy data. From a patient care perspective, liquid biopsy represents a shift toward precision and personalization. It enables a proactive approach to cancer care catching relapses earlier, minimizing unnecessary treatments, and improving overall patient experience. For orthopedic oncologists, it provides a powerful tool to complement traditional diagnostics and guide evidence-based clinical decisions [10].

Conclusion

Liquid biopsy is poised to redefine the landscape of orthopedic oncology by offering a non-invasive, dynamic, and precise method of tumor profiling. While still in its early stages of adoption, the clinical applications are vast from initial diagnosis and treatment selection to ongoing monitoring and detection of recurrence. The integration of liquid biopsy into the multidisciplinary care model enhances the ability to deliver tailored, data-driven treatment strategies, ultimately improving outcomes for patients with bone and soft tissue tumors. Continued research, technological refinement, and collaborative efforts are essential to fully realize the potential of liquid biopsy and to establish it as a standard of care in orthopedic oncology. As we enter a new era of non-invasive cancer diagnostics, liquid biopsy stands at the forefront of innovation, promising a more personalized and less invasive future for musculoskeletal oncology patients.

References

1. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) . Biometrics 44: 837-845.

   , ,

2. Hogan D, Lan LTT, Diep DTN, Gallegos D, Collins PF, et al. (2017) . J Hum Nutr Diet 30: 83-89.

   , ,

3. Collins PF, Elia M, Kurukulaaratchy RJ, Stratton RJ (2018) . Clin Nutr 37: 144-148.

   , ,

4. Pinzón-Espitia O, Pardo-Oviedo J, Ibáñez-Pinilla M (2021) . Nutr Hosp 38: 464-469.

   , ,

5. Chen R, Xing L, You C, Ou X (20180 . Eur J Intern Med 57: 70-75.

   , ,

6. Grönberg AM, Slinde F, Engström CP, Hulthén L, Larsson S, et al. (2005) . J Hum Nutr Diet 18: 445-452.

   , ,

7. Remels AHV, Gosker HR, Langen RCJ, Schols AMWJ (2013) . J Appl Physiol 114: 1253-1262.

   , ,

8. Rabito EI, Marcadenti A, Da-Silva-Fink J, Figueira L, Silva FM, et al. (2017) . Nutr Clin Pract 32: 526-532.

   , ,

9. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, et al. (2003) . Clin Nutr 22: 415-421.

   , ,

10. Skipper A, Coltman A, Tomesko J, Charney P, Porcari J, et al. (2020) . J Acad Nutr Diet 120: 669-708.

    , ,